Albert Vanderlaan is a partner in Orrick’s Technology Companies Group. He works with public and private companies, venture capital firms and investment banks focused on the life sciences and high-growth technology sectors.
Albert is involved in a broad range of corporate legal engagements for high growth technology companies, including venture financings, public offerings, private and public company securities law compliance matters and mergers and acquisitions. He also regularly advises private and public companies and their board of directors on corporate governance issues. Albert's clients include private and public companies in the life sciences (including, among others, immuno-oncology, gene therapy, restorative cell therapy and medical device), real estate, finance and Internet related industries. He also represents underwriters in initial public offerings, follow-on offerings and PIPE offerings and venture capital firms in a variety of investment transactions.
Histogenics Corporation in its reverse merger with Ocugen, Inc.
A syndicate of institutional investors in the pre-IPO convertible note financing of Phathom Pharmaceuticals, Inc.
ARMO BioSciences, Inc. in its acquisition by Eli Lilly for $1.6 billion
Vanda Pharmaceuticals Inc. in its $101 million follow-on public offering
Histogenics Corporation in its $17 million follow-on public offering
Histogenics Corporation in its $6.325 million registered direct offering
Synchronoss Technologies, Inc. in its sale of Intralinks Holdings, Inc. for $977 million
Partner Therapeutics, Inc. in its acquisition of assets related to Leukine from sanofi-aventis U.S. LLC
Synchronoss Technologies, Inc. in its acquisition of Intralinks Holdings, Inc. for $821 million
REGENXBIO Inc. in its $250 million IPO
Synchronoss Technologies, Inc. in its $230 million offering of 0.75% senior convertible notes
Vitae Pharmaceuticals, Inc. in its acquisition by Allergan for $639 million
Please read before sending e-mail.
Please do not include any confidential, secret or otherwise sensitive information concerning any potential or actual legal matter in this e-mail message. Unsolicited e-mails do not create an attorney-client relationship and confidential or secret information included in such e-mails cannot be protected from disclosure. Orrick does not have a duty or a legal obligation to keep confidential any information that you provide to us. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.
By clicking "OK" below, you understand and agree that Orrick will have no duty to keep confidential any information you provide.